Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/03007995.2021.1920381 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Re: Iglay K, Hannachi H, Engel SS, et al. Comorbidities in type 2 diabetes patients with and without atherosclerotic cardiovascular disease: a retrospective database analysis. Curr Med Res Opin. 2021. DOI:10.1080/03007995.2021.1895736.
Curr Med Res Opin
August 2021
Department of Internal Medicine, Endocrinology Section, Clinical Centre of Montenegro, Podgorica, Montenegro.
Comorbidities in type 2 diabetes patients with and without atherosclerotic cardiovascular disease: a retrospective database analysis.
Curr Med Res Opin
May 2021
Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA.
The objective of this study was to describe the pattern of comorbidities in patients with type 2 diabetes mellitus with and without atherosclerotic cardiovascular disease. This was a retrospective, cross-sectional analysis of the IQVIA Commercial Data Delivery database. Patients were ≥18 years on their last encounter between 1 October 2014 and 30 September 2015 and had either a type 2 diabetes mellitus diagnosis or a prescription for an oral diabetes medication.
View Article and Find Full Text PDFDistance to glycemic goal at the time of treatment intensification in patients with type 2 diabetes mellitus failing metformin monotherapy in the United States.
Curr Med Res Opin
May 2020
Center for Observational and Real-world Evidence, Merck and Co., Inc, Kenilworth, NJ, USA.
A substantial proportion of patients with type 2 diabetes mellitus (T2DM) do not reach their target HbA1c level on metformin. The objective of this retrospective observational cohort study is to better characterize the distance between HbA1c target and patient's actual HbA1c level (the distance to goal), using a target HbA1c of 7.0% (53 mmol/mol), in patients with T2DM who have started metformin monotherapy.
View Article and Find Full Text PDFDemographic and clinical profiles of type 2 diabetes mellitus patients initiating sitagliptin in the real-world setting.
Curr Med Res Opin
July 2017
a Merck & Co. Inc. , Kenilworth , NJ , USA.
Objective: Dipeptidyl peptidase-4 (DPP-4) inhibitors have been used for the management of type 2 diabetes (T2D) for over a decade; however, there is a limited understanding of the evolution of their use in the real-world setting over this time period. This study evaluated the demographics and clinical characteristics of patients initiating sitagliptin over a 10 year period in the United States.
Research Design And Methods: Quintiles electronic medical records database was used to identify adults with a new prescription of sitagliptin over two 5 year time periods: 2006-2010 (n = 57,604), and 2011-2015 (n = 147,326).
Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus.
Curr Med Res Opin
July 2016
a Merck & Co. Inc. , Kenilworth , NJ , USA.
Objective: Patients with type 2 diabetes (T2DM) often have multiple comorbidities which may impact the selection of antihyperglycemic therapies. The purpose of this study was to quantify the prevalence and co-prevalence of common comorbidities.
Research Design And Methods: A retrospective study was conducted using the Quintiles Electronic Medical Record database.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!